WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2005121093) LXR RECEPTOR MODULATORS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2005/121093    International Application No.:    PCT/FR2005/001139
Publication Date: 22.12.2005 International Filing Date: 09.05.2005
IPC:
C07D 215/58 (2006.01), C07D 209/42 (2006.01), C07D 405/12 (2006.01), C07D 401/12 (2006.01)
Applicants: LABORATOIRES FOURNIER S.A. [FR/FR]; 42 Rue de Longvic, F-21300 CHENOVE (FR) (For All Designated States Except US).
LEBRETON, Luc [FR/FR]; (FR) (For US Only).
MASSARDIER, Christine [FR/FR]; (FR) (For US Only).
DUMAS, Christine [FR/FR]; (FR) (For US Only).
DODEY, Pierre [FR/FR]; (FR) (For US Only).
MASSON, Philippe [FR/FR]; (FR) (For US Only)
Inventors: LEBRETON, Luc; (FR).
MASSARDIER, Christine; (FR).
DUMAS, Christine; (FR).
DODEY, Pierre; (FR).
MASSON, Philippe; (FR)
Agent: HUBERT, Philippe; Cabinet BEAU DE LOMENIE, 158 Rue de l'Université, F-75340 PARIS Cedex 07 (FR)
Priority Data:
04 04958 07.05.2004 FR
Title (EN) LXR RECEPTOR MODULATORS
(FR) MODULATEURS DES RECEPTEURS LXR
Abstract: front page image
(EN)The invention relates to compounds which are derived from benzenesulfonamide of general formula (I) as described in the claims, and to the pharmaceutically acceptable addition salts thereof. The invention also relates to a method for the preparation thereof, pharmaceutical compositions containing them, and to the use thereof as a pharmacologically active substance in the treatment of neurodegeneracy, cardiovascular and inflammatory disease, hypecholesterolemia and diabetes.
(FR)L'invention concerne des composés dérivés de benzènesulfonamide de formule générale (I) telle que définie dans les revendications, et leurs sels d'addition pharmaceutiquement acceptables. Elle concerne également leur procédé de préparation, les compositions pharmaceutiques les contenant, et leur utilisation en tant que substance pharmacologiquement active, notamment dans le traitement des neurodégénérescences, des maladies cardiovasculaires, inflammatoires, des hypercholestérolémies et du diabète.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: French (FR)
Filing Language: French (FR)